Literature DB >> 12957284

BRAF as a potential therapeutic target in melanoma and other malignancies.

David A Tuveson1, Barbara L Weber, Meenhard Herlyn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12957284     DOI： 10.1016/s1535-6108(03)00189-2

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


× No keyword cloud information.
  45 in total

Review 1.  Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Authors:  Gajanan S Inamdar; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Biochem Pharmacol       Date:  2010-05-09       Impact factor: 5.858

2.  QM/MM based 3D QSAR models for potent B-Raf inhibitors.

Authors:  Jae Yoon Chung; Hwan Won Chung; Seung Joo Cho; Jung-Mi Hah; Art E Cho
Journal:  J Comput Aided Mol Des       Date:  2010-04-01       Impact factor: 3.686

Review 3.  Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Authors:  Janice M Mehnert; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

4.  Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo.

Authors:  Sulochana S Bhandarkar; Jacqueline Bromberg; Carol Carrillo; Ponniah Selvakumar; Rajendra K Sharma; Betsy N Perry; Baskaran Govindarajan; Levi Fried; Allie Sohn; Kalpana Reddy; Jack L Arbiser
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

Review 5.  BRAF and MEK gene rearrangements in melanoma: implications for targeted therapy.

Authors:  Pedro Madureira; Ramon Andrade de Mello
Journal:  Mol Diagn Ther       Date:  2014-06       Impact factor: 4.074

6.  Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells.

Authors:  Kaitlyn Le; Erik S Blomain; Ulrich Rodeck; Andrew E Aplin
Journal:  Pigment Cell Melanoma Res       Date:  2013-04-08       Impact factor: 4.693

7.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Authors:  Mitchell Cheung; Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

8.  Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma.

Authors:  Mohamad Krayem; Philippe Aftimos; Ahmad Najem; Tim van den Hooven; Adriënne van den Berg; Liesbeth Hovestad-Bijl; Rik de Wijn; Riet Hilhorst; Rob Ruijtenbeek; Malak Sabbah; Joseph Kerger; Ahmad Awada; Fabrice Journe; Ghanem E Ghanem
Journal:  Cancers (Basel)       Date:  2020-02-22       Impact factor: 6.639

Review 9.  Vemurafenib: the first drug approved for BRAF-mutant cancer.

Authors:  Gideon Bollag; James Tsai; Jiazhong Zhang; Chao Zhang; Prabha Ibrahim; Keith Nolop; Peter Hirth
Journal:  Nat Rev Drug Discov       Date:  2012-10-12       Impact factor: 84.694

10.  Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.

Authors:  Bin Zheng; Joseph H Jeong; John M Asara; Yuan-Ying Yuan; Scott R Granter; Lynda Chin; Lewis C Cantley
Journal:  Mol Cell       Date:  2009-01-30       Impact factor: 17.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.